Kidney Cancer

Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC

By

Susan Moench, PhD, PA-C

Publish Date June 12, 2019

Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.

Combo Shows Promise in Advanced RCC With Brain Metastases

By

Natasha Persaud

Publish Date June 11, 2019

Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.

FDA Approves New First-Line Treatment for Advanced RCC

By

Jody Charnow

Publish Date May 3, 2019

FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.

Surgical Protocol Shows Promise as a New Standard of Care for Oncology Surgery

By

Joyce Pagan

Publish Date April 12, 2019

Implementation of the ERAS protocol has a dramatic effect on outcomes for patients undergoing prostate or renal cancer surgery.

A Case of Treatment-Related Heart Failure With Cabozantinib for Advanced Renal Cell Carcinoma

By

Susan Moench, PhD, PA-C

Publish Date April 5, 2019

Case report illustrates the link between cabozantinib therapy and cardiomyopathy.